Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

  title={Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis},
  author={Min Jun and Celine Foote and Ji‐cheng Lv and Bruce Neal and Anushka Patel and Stephen J. Nicholls and Diederick E. Grobbee and Alan Cass and John Chalmers and Vlado Perkovic},
  journal={The Lancet},

Figures and Tables from this paper

Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis

&ohgr;-3 FA may protect against vascular disease, but the evidence is not clear-cut, and any benefits are almost certainly not as great as previously believed.

Analysis of the Cochrane Review: Fibrates for secondary prevention of cardiovascular disease and stroke.

  • G. Pires da RosaD. LibânioLuís Filipe Azevedo
  • Medicine, Biology
    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology
  • 2017

Use of Fibrates and Cancer Risk: A Systematic Review and Meta-Analysis of 17 Long-Term Randomized Placebo-Controlled Trials

The findings demonstrate that fibrates have a neutral effect on cancer outcomes, however, it is important to continue monitoring their long-term safety profiles.

Effects of fibrates in kidney disease: a systematic review and meta-analysis.

Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials.

The eligible randomized trials of statins versus fibrates were designed to assess short-term lipid outcomes, making it difficult to have certainty about the direct comparative effect on cardiovascular outcomes and mortality, and with the exception of myalgia, use of a statin appeared to have a lower incidence of adverse effects compared toUse of a fibrate.

Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration

fficacy of fibrates for cardiovascular risk reduction in persons with atherogenic yslipidemia : A meta-analysis

Fibrate treatment directed at markers of atherogenic dyslipidemia substantially reduce subsequent vascular event risk, and may be particularly beneficial in patients with guideline-endorsed indications for therapy.

The effect of fibrate–statin combination therapy on cardiovascular events: a retrospective cohort analysis

Fibrate–statin therapy in a population with mixed dyslipidaemia resulted in an improved lipid profile with few side-effects, and decreases in TG allied with modest decrease in cholesterol and an increase in HDL-C, were associated with better prognosis.

Hyperlipidaemia and cardiovascular disease: do fibrates have a role?

The ACCORD Lipid study shows that the combination of low-dose simvastatin and fenofibrate is well tolerated, and is potentially cardioprotective in patients with atherogenic ‘mixed’ dyslipidemia.



Effects of combination lipid therapy in type 2 diabetes mellitus.

The routine use of combination therapy with fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with type 2 diabetes does not support the routine use.

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

Bezafibrate has no effect on the incidence of coronary heart disease and of stroke combined but may reduce the incidenceof non-fatal coronary events, particularly in those aged <65 years at entry, in whom all coronary events may also be reduced.

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonf fatal myocardial infarction, or nonfatal stroke.

Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome

Metabolic syndrome components identify higher CVD risk in individuals with type 2 diabetes, so the absolute benefits of fenofibrate are likely to be greater when metabolic syndrome features are present.